B O O K - American College of Rheumatology

monday
homeostasis in the immune response due to factors including
environmental influences, leads to aberrant gene expression,
contributing to immune dysfunction and in some cases the
development of autoimmunity in genetically predisposed
individuals.
Upon completion of this session, participants should be able to:
• discuss the variety of epigenetic mechanisms controlling gene
expression
• describe examples of dysregulation of epigenetic pathways in
systemic lupus erythematosus and rheumatoid arthritis
• define the relevance of DNA methylation epigenetic changes
to the clinical expression of autoimmune disease such as
systemic lupus erythematosus
ACR Clinical Symposium
4:30 - 6:00 PM
Hall A3
Treatment of Wegener’s Granulomatosis/Microscopic
Polyangiitis: Understanding and Applying the Data
from Recent Clinical Trials cP P/C PS ARS
Moderators: Robert Spiera, MD; Hospital for Special Surgery;
New York, NY
Carol A. Langford, MD, MHS; Cleveland Clinic Foundation;
Cleveland, OH
• describe the data with the use of biologic agents in Wegener’s
granulomatosis /microscopic polyangiitis
• apply the results from clinical trials in Wegener’s
granulomatosis /microscopic polyangiitis to the treatment of
patients with severe, non-severe, and relapsing disease
ACR Concurrent Abstract Sessions
4:30 - 6:00 PM
A402
Infection-related Rheumatic Disease
Moderators: Daniel H. Solomon, MD, MPH; Brigham and
Women’s Hospital; Boston, MA
Cem Gabay, MD; University Hospital of Geneva; Geneva,
Switzerland
4:30 PM
694. Parvovirus B19 Non-Structural Protein NS1 Forms
Adducts with Cellular DNA, Induces Apoptosis, and Is
Condensed in Apoptotic Bodies: A Model for Viral Induction of
Autoantibodies and Systemic Lupus Erythematosus.
Leona Gilbert 3 , Pavan K. Dhanyamraju 3 , Eoin Wallace 3 , Elina
Dadu 3 , Liping Wang 3 , Harry J. Whitlow 3 , Violetta Kivovich 1 and
Stanley J. Naides 2 , 1 Pennsylvania State University, Milton S.
Hershey Medical Center, 2 Quest Diagnostics Nichols Institute,
San Juan Capistrano, CA, 3 University of Jyväskylä, Finland.
48
4:30 PM
Data for the Use of Conventional Immunosuppressive Agents
in the Treatment of Wegener’s Granulomatosis/Microscopic
Polyangiitis
Philip Seo, MD; Johns Hopkins Bayview Medical Center;
Baltimore, MD
4:55 PM
Data for the Use of Biologic Agents in the Treatment of
Wegener’s Granulomatosis/Microscopic Polyangiitis
Ulrich Specks, MD; Mayo Clinic; Rochester, MN
5:20 PM
So How do I Apply the Findings of these Trials to My Patient?:
Opinions from a Case-based Panel Discussion
John H. Stone, MD, MPH; Massachusetts General Hospital;
Boston, MA
David Jayne, MD; Addenbrookes Hospital University of
Cambridge; Cambridge, United Kingdom
Session Overview:
Wegener’s granulomatosis and microscopic polyangiitis are
complex systemic vasculitides for which treatment is commonly
directed by the rheumatologist. In recent years, a number of
important clinical trials have been conducted to investigate
conventional and biologic immunosuppressive therapies. It is
important for the rheumatologist to understand the efficacy
and toxicity of different treatment options and to be able to
apply the findings from recent trials to the care of patients with
Wegener’s granulomatosis or microscopic polyangiitis.
Upon completion of this session, participants should be able to:
• explain the data for the efficacy and toxicity of conventional
immunosuppressive agents in the treatment of Wegener’s
granulomatosis /microscopic polyangiitis
2010 Program Book
4:45 PM
695. Occurrence of Rheumatoid Arthritis-Associated
Autoantibodies in Leishmania Donovani Infection.
Erik Åhlin 1 , Amir Elshafie 2 , Musa A. M. Nur 4 , Sayda Hassan El
Safi 3 and Johan Rönnelid 1 , 1 Clinical Immunology Unit, Uppsala
University, Uppsala, Sweden, 2 Clinical Immunology Unit,
Uppsala University, Uppsala, Sweden. Department of Pathology
and Microbiology, Alribat University Hospital, Khartoum,
Sudan, 3 Department of Microbiology and Parasitology,
Faculty of Medicine, University of Khartoum, Sudan, 4 Unit of
Rheumatology, Alribat University Hospital, Khartoum, Sudan
5:00 PM
696. IL-12p70 Alteration in Antibiotic Treatment of Chlamydia-
Induced Reactive Arthritis (ReA).
Robert D. Inman 1 , Basil Chiu, Alan P. Hudson 3 and John D.
Carter 2 , 1 Toronto Western Hospital, Toronto, ON, Canada, 2 Univ
of South Florida, Tampa, FL, 3 Wayne State Univ Schl of Med,
Detroit, MI
5:15 PM
697. The Efficacy and Safety of Vaccination Against H1N1
in Patients with Rheumatoid Arthritis, Systemic Lupus
Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis.
Ori Elkayam 2 , Sharon Amir 2 , Michal Mandelboim 1 , Ella
Mendelson 1 , Jonathan Wollman 2 , Uri Arad 2 , Daphna Paran 2 ,
David Levartovsky 2 , Irena Wigler 2 and Dan Caspi 2 , 1 Center of
Virology, Sheba Medical Center, 2 Department of Rheumatology,
Tel Aviv Medical Center
5:30 PM
698. Serious Infection in Rheumatoid Arthritis Patients
Switching Anti-Tumor Necrosis Factor Drugs.
Bao-Anh Nguyen-Khoa 2 , Earl L. Goehring, Jr 2 , Kimberly
Alexander 1 , Wei Dong 1 , Pavel Napalkov 1 and Judith K. Jones 2 ,
1
Genentech, South San Francisco, CA, 2 The Degge Group Ltd,
Arlington, VA